- Home
- ATRA vs BIVI Comparison
ATRA vs BIVI Comparison
Compare ATRA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- BIVI
- Stock Information
- Founded
- ATRA 2012
- BIVI 2013
- Country
- ATRA United States
- BIVI United States
- Employees
- ATRA N/A
- BIVI N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- BIVI Health Care
- Exchange
- ATRA Nasdaq
- BIVI Nasdaq
- Market Cap
- ATRA 50.3M
- BIVI 45.1M
- IPO Year
- ATRA 2014
- BIVI N/A
- Fundamental
- Price
- ATRA $10.61
- BIVI $3.11
- Analyst Decision
- ATRA Hold
- BIVI Strong Buy
- Analyst Count
- ATRA 5
- BIVI 2
- Target Price
- ATRA $26.88
- BIVI $40.00
- AVG Volume (30 Days)
- ATRA 143.9K
- BIVI 3.3M
- Earning Date
- ATRA 11-12-2024
- BIVI 11-13-2024
- Dividend Yield
- ATRA N/A
- BIVI N/A
- EPS Growth
- ATRA N/A
- BIVI N/A
- EPS
- ATRA N/A
- BIVI N/A
- Revenue
- ATRA $100,439,000.00
- BIVI N/A
- Revenue This Year
- ATRA $1,190.80
- BIVI N/A
- Revenue Next Year
- ATRA N/A
- BIVI N/A
- P/E Ratio
- ATRA N/A
- BIVI N/A
- Revenue Growth
- ATRA 2111.34
- BIVI N/A
- 52 Week Low
- ATRA $6.50
- BIVI $1.04
- 52 Week High
- ATRA $39.50
- BIVI $56.54
- Technical
- Relative Strength Index (RSI)
- ATRA 51.14
- BIVI 56.34
- Support Level
- ATRA $11.10
- BIVI $2.87
- Resistance Level
- ATRA $14.93
- BIVI $3.85
- Average True Range (ATR)
- ATRA 1.46
- BIVI 0.39
- MACD
- ATRA -0.14
- BIVI 0.01
- Stochastic Oscillator
- ATRA 24.48
- BIVI 51.32
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.